Loading, please wait...
To account for the impending snow storm, the schedule has changed. Eight residents in two time blocks will present today, with the remaining residents to be rescheduled (date TBD). The updated schedule is below. For those who requested parking, please use your original parking pass.
JANURY 2019 RESIDENT SEMINAR
SNOW SCHEDULE:
|
|
ARB 304
|
ARB 305
|
ARB 354
|
ARB 355
|
|
BLOCK 1
12:00 – 12:45 pm
|
Reinitiation of Anticoagulation After a Major Bleeding Event
Lindsey Eble, Pharm.D.
Barnes-Jewish Hospital
|
Antimicrobial therapy in cystic fibrosis
Rosemary Emelue, Pharm.D.
St. Louis Children’s Hospital
|
Revisiting Beta Lactam Allergies
Alex Tryson, Pharm.D.
St. Louis College of Pharmacy/Mercy Hospital St. Louis
|
Getting Excited About Ketamine: The Role of IM Ketamine in Excited Delirium Syndrome
Tiffany Hopkins, Pharm.D.
Barnes-Jewish Hospital
|
|
BLOCK 2
12:45 – 1:30
|
Current Recommendations for the Use of Antiplatelet Therapy in Secondary Prevention of Non-Cardioembolic
Ischemic Stroke
Sarah Tortora, Pharm.D.
Christian Hospital
|
Evaluation of Intratracheal Budesonide-Surfactant for Prevention of Bronchopulmonary Dysplasia
Brianna Henson, Pharm.D.
SSM Health Cardinal Glennon Children’s Hospital
|
Voriconazole-associated Squamous Cell Carcinoma Post-lung Transplant
Alicia Yn, Pharm.D.
Barnes-Jewish Hospital
|
Escalated Antiarrhythmic Therapy or Ablation for Recurrent Ventricular Tachycardia
Nicholas Greenwald, Pharm.D.
SSM Health Saint Louis University Hospital
|
** Up to 0.75 hours of CE credit are available for each activity, for a maximum possible 1.5 hours if participants attend activities in all time blocks.**
| DOWNLOAD A SCHEDULE » | DOWNLOAD EVALUATION TEMPLATE » | CE INSTRUCTIONS » | *REQUEST PARKING* » | MAP & DIRECTIONS » |
*All parking spaces are filled. No more requests for parking can be accepted at this time.*
REGISTRATION & PARKING INFORMATION
This event has mutliple concurrent sessions. To register, click the green button below. You will be asked to log in. You will be registered for the whole day - please complete the evaluations for only those sessions that you attend. Unattended sessions will be removed from your account, based on sign-in records, within a week following Seminar.
Registration is free, but is required in advance. Due to limited space, only those participants who register before 12:00 PM on Tuesday, January 8, 2019 will be able to request parking access on campus.
To request parking, please first register for your desired sessions. Then, complete the parking questionnaire using the link above, or by clicking here », to complete your parking request. If you do not request parking on our campus, or if you do not submit your requst by the deadline, you will be re-directed upon arrival. A temporary parking pass will be emailed to the address you provide in the separate parking request form on the day prior to the event.
| MAP & DIRECTIONS » | REQUEST PARKING » |
HANDOUTS
Paper copies of handouts will be provided in each room as well as electronically on this website. Copies of PowerPoint slides are not provided. To access the handouts electronically, participants should ensure they are logged in before accessing this event. Click the + symbol beside the session, which will expand the module. A clickable text link to download the handout as a PDF file will be present.
ATTENDANCE
All participants will be required to sign in on the paper sheets, located within each room. Paper sign-in sheets will be reconciled against electronic credit reporting on this website.
CPE CREDIT
Participants must claim all CPE credit electronically. Participants may claim no more than one 45-minute session for each time block. Additional instructions can be downloaded above or read below.
SPECIAL ACCOMMODATIONS
If you require special accommodations, please notify us in advance. Every effort will be made to make accommodations where necessary.
Date: Jan 11, 2019 01:00 PM - 03:40 PM
Location: Academic & Research Building
Fee
$0.00
CE Hours
6.00
Registration closes on Feb 01, 2019 12:00 AM
Activity Type
- Knowledge
Target Audience(s)
- Pharmacists
Requirements for CE Credit
In order to receive CPE Credit, participants are required to submit an evaluation for the session.
- Evaluations will be housed online at this web address for 14 days, after which time they will be closed.
- Immediately upon submission of the online evaluation, a report will be automatically generated and submitted to CPE Monitor using the NABP ePID and DOB stored in the participant's account profile.
- Participants should allow up to 48 hours for the credit to sync with their online NABP e-Profiles. Paper statements of credit are not provided.
- Only ONE session may be claimed per each time block - if multiple concurrent sessions are claimed, participants forfeit CE credit. All CE claims will be cross-checked against the sign-in sheets.
If you experience difficulty, please contact our office so that we may assist you. We are happy to help!
Participants are responsible for ensuring accuracy of credit reporting and receipt of credit. It is recommended that participants log on and reivew the information under "my account" prior to submitting the evaluation. NABP ePID and date of birth must be accurate for credit reporting to occur. Evaluations cannot be reopened after 14 days.
Participants are encouraged to check their NABP eProfiles for receipt of credit within one week of submitting their evaluation(s). If a participant notices an error in credit on their NABP e-profile, they are encouraged to contact our office as soon as possible. To best comply with ACPE's CE credit reporting policy, St. Louis College of Pharmacy is unable, for any reason, to award or correct CE credit if more than 60 days have passed from the event.
ALL PARKING SPACES ARE FILLED. NO MORE REQUESTS FOR PARKING CAN BE ACCEPTED AT THIS TIME.
** Parking must be requested no later than Tuesday, January 8, 2019 at 12:00 PM (CST). **
You should not request parking if you already have a STLCOP parking hang tag, plan to carpool and someone else is driving, or have an alternate mode of transportation.
Registration closes on Feb 01, 2019
at 12:00 AM
Registration closes on Feb 01, 2019
at 12:00 AM
Registration Closed
Registration Closed
Objectives
- Identify risk factors for thrombosis and hemorrhage that may impact the decision to restart anticoagulation.
- Recommend an oral anticoagulant plan for a patient after a major bleed, including if therapy should be restarted, a desired agent and optimal timing.
Activity Number
0033-0000-18-122-L01-P
Date:
01/11/19
Time:
02:40 PM - 03:35 PM
CE Hours
0.75
Location
ARB 304
Registration Closed
Registration Closed
Registration Closed
Objectives
- Describe the epidemiology, incidence, and outcomes related to CF pulmonary exacerbations.
- Summarize the cystic fibrosis pulmonary guidelines for the treatment of pulmonary exacerbations.
- Review literature supporting treatment options for combination therapy in pediatric CF pulmonary exacerbations.
Activity Number
0033-0000-18-123-L01-P
Date:
01/11/19
Time:
12:00 PM - 12:45 PM
CE Hours
0.75
Location
ARB 305
Registration Closed
Registration Closed
Registration Closed
Objectives
- Recognize the incidence of true allergic reactions in patients who report a penicillin allergy.
- Recognize the molecular structure of beta lactam antibiotics and the mechanistic predictors of cross-reactivity.
- Identify the potential clinical consequences/complications associated with use of suboptimal antibiotic therapy in patients with a reported penicillin allergy.
Activity Number
0033-0000-18-117-L01-P
Date:
01/11/19
Time:
12:00 PM - 12:45 PM
CE Hours
0.75
Location
ARB 354
Registration Closed
Registration Closed
Registration Closed
Objectives
- Identify the clinical features associated with Excited Delirium Syndrome.
- Compare and contrast current pharmacologic treatment options for Excited Delirium Syndrome.
- Recommend intramuscular ketamine at an appropriate dose for a patient with Excited Delirium Syndrome.
Activity Number
0033-0000-18-126-L01-P
Date:
01/11/19
Time:
12:00 PM - 12:45 PM
CE Hours
0.75
Location
ARB 355
Registration Closed
Registration Closed
Registration Closed
Objectives
- Identify modifiable and non-modifiable risk factors of recurrent atherosclerotic cardiovascular events.
- Evaluate guidelines with regard to the use of antiplatelet therapy for prevention of recurrent ischemic stroke.
- Interpret recent literature regarding dual antiplatelet therapy in secondary prevention of non-cardioembolic ischemic stroke to identify when and in whom this strategy is appropriate.
Activity Number
0033-0000-18-118-L01-P
Date:
01/11/19
Time:
12:45 PM - 01:30 PM
CE Hours
0.75
Location
ARB 304
Registration Closed
Registration Closed
Registration Closed
Objectives
- Determine which patients are candidates for intratracheal budesonide-surfactant therapy.
- List the benefits of intratracheal budesonide-surfactant in premature infants for the prevention of BPD.
Activity Number
0033-0000-18-131-L01-P
Date:
01/11/19
Time:
12:45 PM - 01:30 PM
CE Hours
0.75
Location
ARB 305
Registration Closed
Registration Closed
Registration Closed
Objectives
- Identify the possible mechanism of voriconazole-induced phototoxicity.
- Identify the risk factors associated to the development of squamous cell carcinoma post-transplant.
Activity Number
0033-0000-18-116-L01-P
Date:
01/11/19
Time:
12:45 PM - 01:30 PM
CE Hours
0.75
Location
ARB 354
Registration Closed
Registration Closed
Registration Closed
Objectives
- Identify the potential complications of ICD shocks.
- Explain the efficacy behind the use of catheter ablation.
- Evaluate potential therapy modifications for a patient with recurrent ventricular tachycardia, despite use of antiarrhythmic medications.
Activity Number
0033-0000-18-124-L01-P
Date:
01/11/19
Time:
12:45 PM - 01:30 PM
CE Hours
0.75
Location
ARB 355
Registration Closed
Registration Closed
Registration Closed
Objectives
- Identify opioid withdrawal symptoms and the timeline in which these symptoms will most likely occur.
- Utilize clinical monitoring tools (such as the Clinical Opioid Withdrawal Scale [COWS] or the Subjective Opioid Withdrawal Scale [SOWS]) to make pharmacological treatment recommendations.
- Evaluate the safety and effectiveness of evidence-based medication-assisted therapies for opioid withdrawal and detoxification in specific patient populations.
Date:
01/11/19
Time:
01:00 PM - 01:45 PM
Location
ARB 305
Registration Closed
Registration Closed
Registration Closed
Objectives
- Identify patients who are candidates to receive dual antiplatelet therapy.
- Evaluate the safety and efficacy of triple versus dual antithrombotic therapy based on the available literature pertaining to patients with atrial fibrillation and coronary artery disease.
- Assess the appropriateness of an antithrombotic regimen for a patient with coronary artery disease and atrial fibrillation.
Date:
01/11/19
Time:
01:00 PM - 01:45 PM
Location
ARB 336
Registration Closed
Registration Closed
Registration Closed
Objectives
- Select the most appropriate medication for treatment of moderate to severe psoriasis.
- Identify precautions and contraindications to the use of biologics for psoriasis.
- Recommend the use of a biologic for psoriasis based on the latest available literature.
Date:
01/11/19
Time:
01:55 PM - 02:40 PM
Location
ARB 304
Registration Closed
Registration Closed
Registration Closed
Objectives
- Describe the pharmacokinetic profile of cabotegravir.
- Identify an appropriate dosing regimen based on current studies for the use of long-acting cabotegravir for PrEP therapy.
- Identify an appropriate dosing regimen based on current studies for the use of long-acting cabotegravir for HIV treatment
Date:
01/11/19
Time:
02:50 PM - 03:35 PM
Registration Closed
Registration Closed
Registration Closed
Objectives
- Identify patients who are most likely to benefit from the use of medical marijuana for chronic non-cancer pain.
- Describe drug interactions with marijuana.
Date:
01/11/19
Time:
01:55 PM - 02:40 PM
Location
ARB 305
Registration Closed
Registration Closed
Registration Closed
Objectives
- Identify the benefit of pimavanserin's mechanism of action in Parkinson's Disease Psychosis.
- Compare the safety of pimavanserin to other atypical antipsychotics in Parkinson's Disease Psychosis.
Date:
01/11/19
Time:
02:50 PM - 03:35 PM
Location
ARB 305
Registration Closed
Registration Closed
Registration Closed
Objectives
- Identify drug class properties of PCSK9 inhibitors.
- Recommend an appropriate regimen of PCSK9 inhibitors for cholesterol management.
- Evaluate guideline recommendations regarding place of therapy for PCSK9 inhibitors.
Date:
01/11/19
Time:
02:50 PM - 03:35 PM
Location
ARB 336
Registration Closed
